The upcoming earnings report for Azenta, Inc. (AZTA) is scheduled for Tuesday, May 5th. Analysts estimate an EPS of $0.1 for this quarter.
Azenta, Inc. (AZTA) is currently priced at $23.91, showing a decrease of $1.25 (-4.95%) from the previous close of $25.15. The trading volume is $96,200, representing a 9.97% change relative to the average volume.
In the most recent quarterly earnings report on Tuesday, February 3rd, AZTA had an EPS of -34 cents. The company reported a net loss of $15.43 million.
Azenta, Inc. demonstrated a positive cash flow trend with free cash flow of $14.65 million and a net cash increase of $55.30 million. Operating cash flow stood at $20.85 million, reflecting a healthy financial position.
The income statement reveals a gross profit of $63.71 million, offset by operating expenses of $68.58 million. AZTA reported an operating income of -$4.88 million and a net loss of $15.43 million.
Key financial ratios indicate challenges for AZTA, including negative profit margins and returns. The company's price to earnings ratio stands at -24.75, reflecting the current market sentiment.
Azenta, Inc. shows total assets of $2 billion, with cash and cash equivalents amounting to $339 million. The company has total liabilities of $359.60 million.
This comprehensive analysis provides insights into AZTA's recent performance, highlighting both challenges and potential opportunities for investors.
Azenta, Inc. provides life science sample exploration and management solutions for the life sciences market in North America, Europe, China, the Asia Pacific, and internationally. The company operates through two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold sample management systems for compound and biological sample storage; equipment for sample preparation and handling; consumables; and instruments that help customers in managing samples throughout their research discovery and development workflows. The Life Sciences Services segment provides comprehensive sample management programs, integrated cold chain solutions, informatics, and sample-based laboratory services to advance scientific research and support drug development. This segment's services include sample storage, genomic sequencing, gene synthesis, laboratory processing, laboratory analysis, biospecimen procurement, and other support services. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Chelmsford, Massachusetts.